1321N1/P2Y1 Stable Cell Line
Recombinant 1321N1 cells stably overexpress human purinergic receptor P2Y1 (P2Y1) on the surface and contain high levels of G protein Gαq to couple with the receptor in downstream signaling pathways.
| 询价 | |
| M00250 | |
|
|
|
|
|
|
|
|
|
| 询价 | |
| M00250 | |
|
|
|
|
|
|
|
|
|
| Product Description | Recombinant 1321N1 cells stably overexpress human purinergic receptor P2Y1 (P2Y1) on the surface and contain high levels of G protein Gαq to couple with the receptor in downstream signaling pathways. |
| Culture Properties | Adherent. |
| Stability | Stable through more than 16 passages with no significant changes in assay performance or expression profile. |
| Size | Two vials of frozen cells (>1×106 per vial in 1 mL) |
| Storage | Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
| Culture Medium | DMEM, 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies) |
| Complete Growth Medium | DMEM (Cat. No. 10569, Life Technologies), 10% FBS |
| Freeze Medium-DATA | 45% culture medium, 45% FBS (Cat. No. 10099-141, Life Technologies), 10% DMSO (Cat. No. D2650, Sigma). |
Figure 1: ADP-induced concentration-dependent stimulation of intracellular calcium mobilization in 1321N1/P2Y1 cells. The cells were loaded with Calcium-4 (Cat. No. R8142, Molecular Devices) prior to stimulation with a P2Y1 receptor agonist, ADP. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses (5-fold dilution) of ADP (Mean ± SEM, n = 3). The EC50 of ADP on P2Y1 in 1321N1 cells was 10.49 nM.
Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is ∆RFU and starts at Bottom and goes to Top with a sigmoid shape. »
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
